US 6554611

I'll run targeted searches for this patent number and its litigation/docket presence.

Let me check specifically for any 2026 CAFC docket activity and confirm the full claim set.

US Patent 6,554,611 — Analyst Summary

Important source note: Your instruction said not to auto-correct identifiers, so I flag a genuine discrepancy rather than resolve it. The authoritative patent record and the Federal Circuit opinion identify the patent as 6,554,611 ("the '611 patent"). However, one Align Technology press release (reproduced in SEC filings) renders it as "US Patent No. 6,544,611." I cannot confirm from the searched sources whether 6,544,611 is simply a typo in that press release or a distinct patent; the litigation and patent records I found consistently use 6,554,611. I am answering for 6,554,611.

Bibliographic data

Continuity (literal): 10/159,242 is a continuation of 09/466,353 (now US 6,398,548), which was a continuation of PCT/US98/12861 (filed Jun. 19, 1998), which was a continuation-in-part of 08/947,080 (now US 5,975,893, filed Oct. 8, 1997), claiming priority from provisional 60/050,342 (filed Jun. 20, 1997).

Abstract (as granted)

"A system for repositioning teeth comprises a plurality of individual appliances. The appliances are configured to be placed successively on the patient's teeth and to incrementally reposition the teeth from an initial tooth arrangement, through a plurality of intermediate tooth arrangements, and to a final tooth arrangement. The system of appliances is usually configured at the outset of treatment so that the patient may progress through treatment without the need to have the treating professional perform each successive step in the procedure."

Claim overview (plain language)

Claim 1 (the only independent claim) — a system for repositioning teeth, comprising a plurality of dental incremental position-adjustment appliances:

• a first appliance shaped/selected to move teeth from the initial arrangement to a first intermediate arrangement;
• one or more intermediate appliances selected to progressively move teeth from the first intermediate arrangement through successive intermediate arrangements;
• a final appliance selected to move teeth from the last intermediate arrangement to the final arrangement; and
• instructions specifying that the patient wear the appliances in a predetermined order that progressively moves the teeth toward the final arrangement, together with a package containing the first, intermediate, and final appliances, wherein the appliances are provided in a single package to the patient.

In short: a kit/set of ≥3 staged aligners supplied in one package to the patient with ordering instructions.

Dependent claims (all trace back to claim 1):

• 2 — the appliances are polymeric shells with cavities shaped to receive and resiliently reposition teeth.
• 3 — successive appliances' cavity-defined tooth positions differ by no more than 2 mm.
• 4 — at least two intermediate appliances.
• 5 — at least ten intermediate appliances.
• 6 — at least twenty-five intermediate appliances.
• 7 — at least some appliances are marked to indicate their order of use.
• 8 — marked with sequential numbering directly on the appliances.
• 9 — marked on tags affixed to the appliances.
• 10 — marked by placement in a pouch.

Note: the granted claims quoted here match the text recited in the Federal Circuit opinion and on Justia; the Google Patents "definitions/landscape" extract provided in my source did not reproduce the claim set verbatim, so the claim language above is drawn from the CAFC opinion and Justia claim listing.

Litigation / docket status

• Ormco Corp. v. Align Technology, Inc., No. 05-1426 (Fed. Cir., 463 F.3d 1299), decided Aug. 30, 2006; rehearing and rehearing en banc denied Oct. 26, 2006. The CAFC reversed the C.D. Cal. summary judgment and held claims 1, 2, 3, and 7 of the '611 patent invalid as obvious under §103(a) (in view of Dr. Truax's prior practice/instruction sheet and FDA labeling regulations). Identifiers for related CAFC material: litigation link .../case/05-1426; opinion PDF at cases.justia.com.
• The same appeal also invalidated claims 10 and 17 of US 6,398,548. Align's Aug. 31, 2006 press release confirms the '611 patent has ten claims, with the ruling touching only claims 1, 2, 3, and 7.
• The case was an appeal from a permanent injunction (entered Mar. 26, 2006 by Judge Gary L. Taylor, C.D. Cal., SA CV 03-16-GLT) that had previously been granted after a finding that Ormco's "Red, White & Blue" product infringed claims 1–3 and 7 of the '611 patent.
• Family-level first worldwide litigation record exists (Darts-IP family 40090178).
• The patent is also cited as prior art / background in later Align and ClearCorrect proceedings (e.g., PTAB IPR2025-00817 and IPR2025-00821 involving ClearCorrect, and W.D. Tex. litigation over later Align "materials," "treatment planning," and "composite image" patents), but those do not assert the '611 patent.

Uncertainty / gaps — stated explicitly

• No CAFC 2026 docket activity for patent 6,554,611 was found in my searches. The only CAFC appellate matter I could substantiate is the 2006 Ormco decision (No. 05-1426). I could not access the USPTO PatentCenter/PTAB APIs directly in this session, so my "no 2026 activity" statement is limited to the web sources searched and should not be treated as an exhaustive docket clearance.
• I could not independently verify the "6,544,611" vs "6,554,611" rendering discrepancy; treat the primary identifier as 6,554,611.
• Claim-by-claim text for claims 4–6, 8–10 is quoted from the Justia claim listing; I did not see those exact strings reproduced in the CAFC opinion (which addressed only claims 1, 2, 3, 7), so minor wording risk exists for those dependent claims.

Would you like me to attempt to pull the USPTO PatentCenter "Patent Trial and Appeal Case Tracking" or assignment history for 10/159,242 to firm up the 2026 docket question?

I'll research litigation involving US Patent 6,554,611 specifically.

Let me gather specific case numbers and details.

Let me verify the ITC investigation and check for any other cases naming the '611 patent.

Litigation involving U.S. Patent No. 6,554,611

I searched litigation databases/sources (Unified Patents portal, CourtListener/RECAP, Justia, WorldLII, ITC Federal Register notices, and Align Technology's SEC disclosures). One contested litigation matter involving the '611 patent exists, plus a related appellate proceeding. I did not find any litigation naming the '611 patent in any other case (no ClearCorrect case, no SmileDirectClub case, no IPR/PGR, no ITC investigation).

Note on scope: the '611 patent (a continuation of the family tracing to provisional 60/050,342, filed 1997-06-20) issued 2003-04-29 and reached its anticipated expiration 2017-10-08. Google Patents lists one "first worldwide family litigation" entry (Darts-IP family 40090178) and one CAFC case link — the same matter described below.

1. Ormco Corp. v. Align Technology, Inc. (and Allesee Orthodontic Appliances, Inc.)

Procedural history and outcome (as to the '611 patent):

• June 30, 2004 (Align filings also describe a July 2, 2004 order): the district court granted Align's summary-judgment motion in part, finding Ormco and AOA infringed claims 1–3 and 7 of the '611 patent (and claims 1–3, 10–13, 17 of the '548 patent). The court construed claim 1 of the '611 patent to require only that the appliances be "capable of being provided [to patients] in a single package."
• November 4, 2004: summary judgment rejecting Ormco/AOA's inequitable-conduct defense and holding the asserted '611 claims not invalid.
• February 24, 2005: on cross-motions, the court held claim 1 of the '611 patent not invalid over the Truax and Rains prior-use references; claims 2, 3, 7 (and 8) not anticipated/not obvious. (In the same ruling the court held claims 1–3 and 11–13 of the '548 patent invalid as anticipated by Rains.)
• May 26, 2005: the court entered a permanent injunction barring Ormco/AOA from infringing claims 1–3 and 7 of the '611 patent and claims 10 and 17 of the '548 patent. (The CAFC opinion recites the injunction as entered "March 26, 2006," which appears to be an error; Align's SEC filings and the docket sequence support May 26, 2005.)
• February 1, 2006: settlement agreement — Ormco/AOA to pay $884,000 into escrow to resolve past damages, willfulness and attorneys' fees, released to Align only if a final, non-appealable judgment found infringement of at least one claim of the Align patents.
• Appeal — Court of Appeals for the Federal Circuit, No. 05-1426 (Ormco/AOA's appeal of the permanent injunction, plus Align's cross-appeal).
• CAFC decision (2006), reported at 463 F.3d 1299: the Federal Circuit reversed, holding claims 1, 2, 3 and 7 of the '611 patent invalid as obvious (and claims 10 and 17 of the '548 patent invalid as obvious) over the Truax/Rains prior art. The court also affirmed the district court's rulings that 86 claims of Ormco's own patents were not infringed and were invalid/non-enabled.
• Consequence: because the CAFC issued a final, non-appealable judgment of invalidity as to each asserted Align claim, all escrowed funds were returned to Ormco and AOA — Align never collected. Align's '611 patent claims were thus judicially invalidated in 2006.
• Post-appeal: Ormco petitioned the U.S. Supreme Court (petition filed February 14, 2008) regarding the portion of the CAFC ruling on Ormco's own 86 claims — that petition did not concern the '611 patent.

Current status: Terminated/closed. The '611 patent expired (anticipated expiration 2017-10-08) and its asserted claims stand invalidated by the 2006 CAFC decision.

2. Related Align–OrthoClear matters — the '611 patent was NOT asserted

For completeness, and to avoid confusion with similar Align patents, the OrthoClear litigation did not involve the '611 patent:

Coverage gaps / caveats (stated explicitly)

• No IPR, PGR, or CBM challenging the '611 patent was found. The PTAB proceedings I saw in this space (e.g., ClearCorrect's IPR2016-00270) target other Align patents such as the '037 patent.
• No later district-court litigation naming the '611 patent (e.g., against ClearCorrect or SmileDirectClub) was found. Those later Align campaigns asserted other patents in the family ('511, '880, '575-type patents, etc.).
• I found an Align SEC disclosure referencing a USPTO Final Office Action dated June 23, 2006 in a post-grant (reexamination) context, but I could not confirm from the retrieved sources whether that action pertained to the '611 patent or to a different Align patent (reissue/reexamination certificates cited by Align cover '215, '548, '863, '325, '880, '994 and '893). Reexamination is in any event a USPTO proceeding, not "litigation" — treat this item as unverified.
• Case-number caution: the authoritative district-court number for the Ormco matter is SA CV 03-16-GLT (C.D. Cal.), as recited in the Federal Circuit's opinion. Align's SEC filings describe the venue as "Central District, Orange County Division" and give no number; treat "SA CV 03-16-GLT" as the reliable citation.
• Date conflict, flagged rather than resolved: the CAFC opinion states the permanent injunction was entered "March 26, 2006," whereas Align's contemporaneous filings state May 26, 2005, and describe the appeal as noticed May 31, 2005. These cannot both be correct; I have used May 26, 2005 and noted the discrepancy.
• The Google Patents page for US6554611B2 links the CAFC matter as case 05-1426 at https://portal.unifiedpatents.com/litigation/Court%20of%20Appeals%20for%20the%20Federal%20Circuit/case/05-1426, which corroborates appellate case number 05-1426.

Primary sources consulted

• Federal Circuit opinion: https://cases.justia.com/federal/appellate-courts/cafc/05-1426/05-1426-2011-03-27.pdf; also 463 F.3d 1299 at https://law.resource.org/pub/us/case/reporter/F3/463/463.F3d.1299.05-1426.html and http://www.worldlii.org/us/cases/federal/USCAFED/2006/157.html
• ITC notice of investigation, Inv. No. 337-TA-562: https://www.usitc.gov/secretary/fed_reg_notices/337/337-ta-562.notice.1151590320_0.pdf
• ITC consent order/stipulation and Align's 10-Q litigation summaries: https://investor.aligntech.com/static-files/cc1e0e94-0523-43d5-93a0-b5d76c93564d and https://aligntech.gcs-web.com/static-files/3bb31f01-c807-4a6e-8b31-77d3acbce114
• CourtListener docket for Align v. OrthoClear, 3:05-cv-02948: https://www.courtlistener.com/docket/5734805/align-technology-inc-v-orthoclear-inc/
• Google Patents family/litigation links for US6554611B2: https://patents.google.com/patent/US6554611B2/en

I'll start by checking the structured data and then searching for any proceedings the ODP ingest may have missed.

Let me run additional targeted checks for any AIA trial filings, and confirm the litigation history details.

Let me do a final sweep for any later litigation or AIA petitions naming the '611 patent.

PTAB / AIA Trial Proceedings — US 6,554,611

Bottom line up front: There are zero AIA trial proceedings on this patent. The structured "PTAB proceedings on file" block — sourced from the USPTO Open Data Portal — reports no IPR, PGR, or CBM for US 6,554,611, and my independent web sweep for any petition, institution decision, or FWD naming the '611 patent (or its sibling '548) returned nothing at the Board. I found no PTAB proceeding numbers to report, and I will not manufacture any.

The patent's validity story ran entirely through Article III, not the PTAB — and it ended badly for the patent owner. That substitute record is set out below, clearly labeled as not an AIA proceeding, because it is what actually matters to a defendant today.

Proceedings overview

Total AIA trial proceedings on file: 0 (0 active, 0 claims invalidated by the Board, 0 claims sustained by the Board, 0 settled, 0 institution denials). Because no petition was ever filed, there is no PTAB estoppel, no FWD to quote, and no Board appeal — the patent's validity was instead litigated to a Federal Circuit judgment invalidating asserted claims 1, 2, 3, and 7 of the '611 patent as obvious, a holding reported in Align's own SEC filings as resulting in a "final, non-appealable judgment of invalidity with respect to each asserted claim." Combined with the patent's expiration on 2017-10-08 (per the Google Patents legal-status record: "Expired - Lifetime"), the defensive posture for a defendant is strong — stronger than a "hardened patent" would be. This is not a case where the absence of IPRs signals a patent that scared off challengers; it is a case where the four claims Align actually asserted were killed in district court and on appeal years before the AIA trial regime even existed.

⚠️ Identifier caveat (per operating rules, no auto-correction): Align's 2006 press release and several of its SEC filings describe this patent as "US Patent No. 6,544,611" in places, and as "6,554,611" in others. The patent in suit and on appeal — and the patent in the authoritative full text above — is US 6,554,611. The "6,544,611" string appears to be a typographical error in those filings, but I am flagging it literally rather than silently normalizing it. Confirm which number a demand letter cites before relying on any of this.

No AIA trial proceedings on file

None — Petitioner v. Align Technology, Inc.

• Type: N/A — no Inter Partes Review, Post-Grant Review, or Covered Business Method Review was ever instituted against US 6,554,611.
• Filed: N/A
• Status: N/A (USPTO ODP returns no AIA trial proceedings; not contradicted by any web source I located)
• Judge panel: N/A — no Board panel was ever assigned
• Petition grounds: N/A
• Institution decision: N/A
• Final Written Decision: N/A
• Settlement / termination: N/A
• Appeal: The only Federal Circuit appeal in the record is Article III, not a PTAB appeal — see below.
• Defensive value: You cannot build a § 315(b) time-bar defense, a § 315(e)(2) estoppel argument, or an "IPR instituted, claims canceled" narrative here. You also don't need to. The invalidity work was done by the courts.

Caveat on one adjacent data point: A search surfaced a PTAB docket for IPR2016-00270, an inter partes review of U.S. Patent 6,699,037 (a different Align dental patent), which happens to host a copy of the Ormco v. Align opinion as an exhibit. I did not verify the petitioner, the outcome, or any relationship to the '611 patent. Do not treat that proceeding as relevant to US 6,554,611 without independent confirmation.

The record that actually governs: Article III invalidity (NOT an AIA proceeding)

CAFC 05-1426 — Ormco Corp. & Allesee Orthodontic Appliances v. Align Technology, Inc.

• Type: Federal Circuit appeal from summary judgment — not an AIA trial. Listed here because the "PTAB-only" template would otherwise leave the defendant with nothing actionable.
• Filed / decided: Notice of appeal from the permanent injunction filed 2005-05-31; opinion reported at 463 F.3d 1299, issued in late August 2006 (Align's Form 8-K reports the company learning of the ruling on 2006-08-31). I could not pin the exact issuance day from the sources reviewed, so treat the day as approximate and the month/year as firm.
• Status: Decided — asserted claims invalid. Align's 8-K: the CAFC "declared two out of a total of seventy-one claims in Align's US Patent No. 6,398,548 and four out of a total of ten claims in US Patent No. 6,554,611 to be invalid as 'obvious.'"
• Judge panel: Opinion authored by Judge Dyk (per the reported opinion headnote). Remaining panel members not confirmed in the sources I reviewed — I am not guessing them.
• Grounds: 35 U.S.C. § 103(a) (2000), obviousness. Primary reference: the Truax orthodontic practice and Truax's instruction sheet distributed at seminars/clinics, combined with FDA statutes and regulations requiring instructions with medical devices. Secondary reference discussed in the litigation: the Rains practice. Align also raised § 102(a) public-accessibility arguments against Truax; the court held Truax's practice and instruction sheet were "sufficiently publicly accessible to qualify as prior art."
• Claim-level disposition — quote it exactly:
  • Claim 1 (independent, system claim) — held obvious. The court construed "geometry" to mean "configuration" or "shape," so Truax's appliances of different thicknesses satisfied the "geometries" limitation; and it rejected the district court's construction that "single package" merely requires devices be "capable of" being provided in a single package. On the package limitation the court wrote: "Providing the devices to the patient in one package, as opposed to two packages or three packages is not a novel or patentable feature in the light of the well-known practice of packaging items in the manner most convenient to the purchaser."
  • Claim 2 (depends from claim 1) — held obvious.
  • Claim 3 (depends from claim 2; "differ ... by no more than 2 mm") — held obvious.
  • Claim 7 (depends from "any of claims 1-5 or 6"; appliances "marked to indicate their order of use") — held obvious. The court found that "the thicknesses of Truax's devices served as markings to indicate their order of use."
  • Claims 4, 5, 6, 8, 9, 10 — the Federal Circuit did not address these. The opinion states plainly: "Four claims of the '611 patent are pertinent to this appeal—claims 1, 2, 3, and 7." Do not represent that claims 4-6 or 8-10 were adjudicated invalid. (Note that Align had asserted claim 8 in the district court, and the district court found infringement of only claims 1-3 and 7 — see the CourtListener / Justia opinion.)
• Settlement / termination: A 2006-02-01 settlement agreement between Align and Ormco/AOA resolved past damages, willfulness, and attorneys' fees for the adjudged infringement, with Ormco/AOA paying $884,000 into escrow. Critically, the escrow was contingent on a final, non-appealable judgment that Ormco/AOA infringed at least one Align-patent claim. When that contingency failed, Align's later filing confirms: "the CAFC has now issued a final, non-appealable judgment of invalidity with respect to each asserted claim of the Align Patents, and therefore all funds in the escrow account will be returned to Ormco and AOA."
• Second appeal: CAFC, decided 2007-08-24 (Align's disclosure: "The CAFC issued a ruling on August 24, 2007, affirming the District Court's ruling that 86 out of 92 claims in Ormco's ... patents are invalid and not infringed by us"; on Align's cross-appeal, the court affirmed invalidity of six claims of the '548 patent — claims 1-3 and 11-13). The August 2007 ruling's cross-appeal portion is directed to the '548 patent; the '611 claims 1-3 and 7 fell in the August 2006 decision and were never restored. Ormco later sought Supreme Court review of the rulings against Ormco, not the '611 invalidity. I found no indication the '611 invalidity holding was disturbed.
• Defensive value: Claims 1, 2, 3, and 7 of US 6,554,611 are invalid as a matter of a Federal Circuit judgment, not merely vulnerable. Any infringement theory premised on those claims is exposed to a Blonder-Tongue / collateral-estoppel attack, and Align's own public filings concede a "final, non-appealable judgment of invalidity with respect to each asserted claim." That is a far better defensive asset than an IPR FWD — it binds the patentee, not just a petitioner and its privies.

Strategic summary

Claim status. Of the ten claims in US 6,554,611: claims 1, 2, 3, and 7 are invalidated (obvious, § 103(a), Fed. Cir. 2006). Claims 4, 5, 6, 8, 9, and 10 are formally untested — the Federal Circuit expressly framed the appeal as touching only claims 1, 2, 3, and 7. But every remaining claim depends (directly or through claim 2/3) from invalid claim 1, and claim 7 itself reads "as in any of claims 1-5 or 6," which tells you claims 4-6 likewise sit under the claim 1 base. The Truax + FDA-instructions rationale that killed claim 1's core limitations — progressive-geometry appliance series, order-of-use instructions, single-package provision — is not a limitation that dependent claims 4-6 or 8-10 are likely to escape without independent added structure. Treat them as doubtful but unadjudicated, and plead around them rather than assuming they are dead.

Estoppel landscape. There is no § 315(e)(2) estoppel anywhere on this patent — no IPR was filed, so no petitioner and no privies are barred. The operative preclusion is the judicially created Blonder-Tongue rule: once a patent claim has been finally adjudged invalid in a full and fair litigation, the patentee is precluded from asserting it against a different defendant. That is materially broader than IPR estoppel, which runs only against the petitioner. Practically: invalidity-based defenses are wide open — no IPR estoppel bars you from raising grounds in district court, and you can affirmatively assert issue preclusion on claims 1-3 and 7. The real constraint is different: the patent expired on 2017-10-08, so there is no prospective conduct to enjoin and damages can only reach pre-expiration activity within the § 286 six-year lookback (i.e., activity before 2017-10-08).

Pattern signals. (1) No petitioner — there is no repeat-filer pattern, no defensive aggregator, and no Unified Patents involvement traceable to this patent in anything I located. (2) The patent owner did not pursue PTAB appeals on this patent, because it never had a PTAB proceeding to appeal; its appellate activity was as cross-appellant in the Ormco litigation. (3) The IPR gap is explained, not suspicious. The four asserted claims were invalidated by the Federal Circuit in 2006 — five years before the AIA created IPR. By the time IPR practice matured, there was nothing left worth challenging and the patent had expired. Contrast this with Align's related patents (5,975,893; 6,398,548; 6,309,215; 6,705,863; 6,217,325; 6,629,840; 6,722,880; 6,318,994), which did attract ex parte reexamination requests filed by a San Francisco law firm on behalf of an unnamed party (widely understood to be OrthoClear). US 6,554,611 does not appear on Align's own reexamination table. That reinforces the read: no one bothered, because the claims were already gone.

Recommended next steps

1. If a demand letter cites claims 1, 2, 3, or 7 — you have a dispositive answer. Cite the Federal Circuit's holding that those four claims were invalid as obvious, and Align's own 8-K language: the CAFC "declared four out of a total of ten claims in US Patent No. 6,554,611 to be invalid as 'obvious.'" Opinion: Ormco Corp. v. Align Tech., Inc., 463 F.3d 1299 (Fed. Cir. 2006) — CourtListener · Justia opinion PDF (docket 05-1426) · law.resource.org reporter text. Align's admission is in its Form 8-K and the press release.
2. Raise Blonder-Tongue / collateral estoppel affirmatively and early, ideally in a motion to dismiss or a motion in limine on invalidity, supported by the Federal Circuit mandate and Align's own "final, non-appealable judgment of invalidity with respect to each asserted claim" statement.
3. Do not file an IPR. There is no live PTAB activity, the patent expired 2017-10-08, and the four asserted claims are already invalidated. Filing an IPR would be a waste of fees and could invite the Board to exercise § 325(d)/discretionary-denial or General Plastic-style considerations; your better forum is the district court on estoppel.
4. Verify current claim status directly before relying on anything above: pull the patent's prosecution and post-grant history from USPTO Patent Center and the patent's trial record from PTAB E2E, and check for any recorded statutory disclaimer, certificate of correction, or reexamination certificate affecting claims 4-6 or 8-10. My conclusion that claims 4-6 and 8-10 are unadjudicated is based on the Federal Circuit opinion's explicit scope language — it is not the same as confirming their current legal status at the Office.
5. If the asserted patent number is "6,544,611" rather than "6,554,611," stop and reconcile the numbers before drafting anything. The two strings appear interchangeably in Align's own 2006 filings, and I have not verified what, if anything, US 6,544,611 covers.

Confidence and gaps. High confidence: zero AIA trial proceedings; the Federal Circuit invalidated claims 1, 2, 3, and 7 of the '611 patent as obvious in 2006; the patent expired 2017-10-08. Lower confidence, flagged above: the exact day of the 2006 opinion; the full Federal Circuit panel composition; the precise validity status of claims 4-6 and 8-10; and any relationship (if any) between this patent and IPR2016-00270 on U.S. 6,699,037.

I'll research the assignment record and ownershiip chain for US 6554611.

I found a key data point (a reel/frame for a related Align filing). Let me dig for records specifically tied to the '611 patent and Align's ownership history.

US 6,554,611 — Ownership & Assignment Record Reconstruction

Patent: US 6,554,611 B2, "Method and system for incrementally moving teeth"
App. No.: 10/159,242 · filed 2002-05-30 · granted 2003-04-29 · priority 1997-06-20 · expired 2017-10-08 ("Expired – Lifetime")
Continuity: continuation of 09/466,353 (now US 6,398,548) → continuation of PCT/US98/12861 → CIP of 08/947,080 (now US 5,975,893) → provisional 60/050,342
Source of record: https://patents.google.com/patent/US6554611/en

Method note / limitation: I could not open the USPTO Assignment Center search UI directly in this session (only web search was available). Google Patents' legal‑events tab for this patent, plus all web-indexed assignment-cover-sheet text I retrieved, contain no recorded assignment whose serial number is 10/159,242. Treat the negative finding below as strong but not a substitute for a manual query at https://assignmentcenter.uspto.gov/ (or https://assignment.uspto.gov/patent/index.html), searching patent number 6554611.

Inventors

Five inventors are named on the face of the '611 patent, per the Google Patents bibliographic data (the same five appear on the family members US 5,975,893, US 6,217,325, US 6,398,548 and EP 1 369 091 / EP 1 929 974):

• All five are named on the Oct. 8, 1997 parent application 08/947,080, whose face reads "Assignee: Align Technology, Inc." — i.e., the inventors were Align personnel/founders at filing (Align was founded in 1997). Chishti and Wirth are the well-known Align co-founders; Chishti appears on the patent face as "Muhammad Chishti" and is commonly known as Zia Chishti — I flag the name equivalence as likely but not verified from a primary USPTO record in this session.
• No "all inventors departed within 12 months" pattern. The opposite is observed: Chishti, Freyburger, Wirth and Lerios recur as inventors on later Align patents through the 2000s (e.g., Chishti/Freyburger on the '874 patent; Chishti/Wirth on the application that became the '880 patent, filed Jan. 14, 2002). This is a continuity-of-inventor pattern typical of an operating company, not a pre-fire-sale pattern.
• Reported (not primary-sourced here): founder Chishti stepped down as Align CEO in 2001, roughly 3.5 years after the 1997 filing — outside the 12-month window that would be a fire-sale tell.

Original assignee

Align Technology, Inc. — named on the issued patent and, per Google Patents, still listed as both original and current assignee. Address of record on the contemporaneous 2002 cover sheet for a sibling Align filing: 881 Martin Avenue, Santa Clara, California 95050; today 2560 Orchard Parkway, San Jose, CA 95131 (per family WO 2011/135438).

• Product embodying the claims: yes. Align ships the Invisalign clear-aligner system; claim 2 of the '611 recites "polymeric shells having cavities shaped to receive and resiliently reposition teeth," which is the Invisalign appliance. Align's own SEC disclosure discusses the '611 patent as covering "a system for repositioning teeth that includes one or more intermediate" appliances (https://aligntech.gcs-web.com/node/14971/html).
• Business: orthodontic/dental devices — clear aligners, scanners, software. Publicly traded (NASDAQ: ALGN) since its 2001 IPO.
• Status: operating. No Chapter 7/11 filing; no dissolution; no acquisition of Align.
• Litigation posture of this patent: Align asserted the '611 as plaintiff/counterclaimant against Ormco Corp. (C.D. Cal., Ormco filed Jan. 6, 2003; Align counterclaimed). The Federal Circuit reversed the infringement judgment on Aug. 30, 2006 and held claims 1–3 and 7 of the '611 invalid for obviousness (Ormco Corp. v. Align Tech., Inc., No. 05-1426). The patent has since expired (2017-10-08), so it is not currently assertable. https://portal.unifiedpatents.com/litigation/Court%20of%20Appeals%20for%20the%20Federal%20Circuit/case/05-1426

Assignment timeline

Finding: No post-issuance assignment record was located for US 6,554,611 / application 10/159,242. Google Patents' legal-events tab for this patent lists only filing (2002-05-30), publication (2002-10-17), grant (2003-04-29) and anticipated expiration (2017-10-08) — no conveyance, no reel/frame, no change of assignee. Both "original assignee" and "current assignee" are Align Technology, Inc. The only family-level litigation flags are the Darts-IP family entry (family 40090178) and CAFC 05-1426; neither is an assignment.

Because there are no recorded post-issuance assignments, I do not fabricate a chain. The only ownership-relevant items that are documented are:

• 1997-10-08 (executed/filed) — Parent application 08/947,080 filed naming the five inventors, with Assignee: Align Technology, Inc. on the face of the resulting US 5,975,893. No reel/frame retrieved. Context: original inventor→company assignment (routine in-house recordation).
• 2002-05-30 (filed) — Application 10/159,242 filed as a continuation directly in the name of Align Technology, Inc.; no intervening transfer is recorded between the 1997 parent and this continuation. Context: internal continuation — same owner throughout.
• Analogue only, NOT this patent (do not attribute to the '611): USPTO Notice of Recordation, Reel 013235/0606, recorded 2002-08-22, 5 pages, doc date 2002-08-20, assignee Align Technology, 881 Martin Avenue, Santa Clara, CA 95050, serial 10/225,889, examiner Violet McCoy, Assignment Division. This is Align's inventor→company assignment cover sheet for a different Align application filed the same week. It is cited here only to show Align's contemporaneous recordation practice (routine, in-house, no NPE-style correspondent or shell assignee).
• 2003-04-29 — '611 patent issues to Align Technology, Inc. (no assignment of record).
• 2017-10-08 — Anticipated expiration; status "Expired – Lifetime." Title never left Align.

If the Assignment Center shows an inventor→Align assignment for 10/159,242 that my searches did not index, it would be a routine pre-issuance recordation and would not change the conclusions below.

Timeline diagram

timeline
    title Ownership of US 6554611
    1997 : Parent app 08 947 080 filed
         : Assigned to Align Technology Inc
    1999 : Parent patent US 5975893 issues to Align
    2002 : Continuation 10 159 242 filed by Align
         : No intervening transfer recorded
    2003 : US 6554611 issues to Align Technology
         : Ormco sues Align over 611 family
    2006 : Federal Circuit holds 611 claims invalid
    2017 : Patent expires with Align as owner

NPE / troll-pattern signals

1. Shell-entity transfer — not present. No assignment of record moves the '611 to any LLC. Assignee of record is Align Technology, Inc., an operating company, from 1997 through expiration in 2017.
2. Known asserter in the chain — not present. No assignee in this chain matches Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, or any Spangenberg entity. Align is the plaintiff/operating company, not an NPE.
3. Repeat correspondent across the chain — not present (no data to support it). No assignment cover sheets exist for this patent in the sources I could reach, so there is no correspondent-of-record to test for recurrence. The single analogue cover sheet retrieved (Reel 013235/0606, 2002-08-22, examiner Violet McCoy) is for a different Align application and shows ordinary in-house recordation — one appearance, not recurrence, and therefore not a finding under the stated rule.
4. Cascading transfers — not present. Zero recorded transfers; no chained LLCs, no <24-month ladder.
5. Pre-litigation transfer — not present. The first suit touching the '611 family (Ormco, Jan. 6, 2003) was filed by Align, which already owned the patent via its internal continuation chain — no arms-length transfer precedes it.
6. Bankruptcy fire-sale — not present. Align has never been in Chapter 7/11; it IPO'd in 2001 and remains a listed operating company.
7. Privateering — not present. No operating-company→NPE transfer; Align asserted in its own name.
8. Defensive aggregator — not present. The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN; it terminates at Align by expiration.

Verdict

Operating-company assertion.

Justification: the assignment record for US 6,554,611 is empty — Google Patents shows no ownership-change event for application 10/159,242, and both original and current assignee are Align Technology, Inc., so no assignment link exists to analyze for NPE traits and the "Insufficient data / no records" branch nearly applies. Substantively, however, the patent was owned and enforced end-to-end by an operating company: Align shipped Invisalign (the polymeric-shell appliance of claim 2) and asserted claims 1–3 and 7 against Ormco (CAFC No. 05-1426), an actual competitor, before those claims were held invalid on Aug. 30, 2006 and the patent expired 2017-10-08. There is no NPE signal of any kind in this chain.

Verification links:

• USPTO Assignment Center (search "6554611"): https://assignmentcenter.uspto.gov/
• USPTO assignment index: https://assignment.uspto.gov/patent/index.html
• Google Patents legal events: https://patents.google.com/patent/US6554611/en
• CAFC 05-1426 (Ormco v. Align): https://portal.unifiedpatents.com/litigation/Court%20of%20Appeals%20for%20the%20Federal%20Circuit/case/05-1426

I'll research the prior art citations for US 6,554,611 using live searches.

Let me try to access the specific citation tables for this patent.

Prior-Art Analysis — US 6,554,611 B2 ("Method and system for incrementally moving teeth")

Method / limitation disclosure up front (important):

1. Tool limit hit. I exhausted my search budget before I could open the USPTO PatentCenter "References Cited" (PTO-1449) page or the Google Patents citation table directly. What follows is therefore grounded in (a) the authoritative full patent text you supplied, which contains the specification's own "Description of the Background Art" citation list, and (b) my training knowledge of the individual references, which I have not been able to re-verify against the USPTO citation table in this session. I flag confidence per row.
2. Date mismatch (flagged, not corrected). This task header says "Current Date: April 26, 2026"; my operating environment says today is 2026-09-29. I am not silently reconciling these.
3. Identifier discipline. All searches were run on the literal string 6554611. My searches surfaced 6554611 only inside the forward-citation lists of later patents (e.g., US 10,265,141; US 10,519,293; US 11,623,368; US 12,121,412) — those are later Align patents citing '611, i.e. not prior art to it, and I have excluded them.
4. Cross-reference note. The previously generated section flagged a "6,544,611" vs. "6,554,611" rendering discrepancy and identified the Truax prior practice + FDA labeling combination as the basis for the CAFC's 2006 invalidity ruling. I build on that rather than repeat it, and I flag that I could not independently re-verify the "Truax" attribution in this session.

Headline finding

No reference cited on the face or in the body of the '611 patent is a true §102 anticipation of granted claim 1. Claim 1 is a combination claim — a kit of ≥3 staged polymeric-shell aligners + written ordering instructions + single package delivered to the patient, all pre-planned at the outset. Every reference below discloses at most a subset. The only prior art that actually defeated claims was used under §103(a), not §102, and was a prior public use/on-sale art, not a patent.

So the accurate framing of your question is: which claims does each reference put at risk, and under which subsection.

Table A — Patent references cited in the '611 specification (the "patent citations")

The specification groups these as follows (authoritative characterization in quotes). Dates marked ⚠ are from my training data, not re-verified against USPTO in this session.

Table B — Non-patent literature / technical references in '611

The single most relevant prior art — and it is not a patent

Per the previously generated section (which I was unable to re-verify here), the art that actually invalidated claims 1, 2, 3, and 7 of '611 was Dr. Truax's prior practice/instruction sheet, combined with FDA labeling regulations, in Ormco Corp. v. Align Technology, Inc., No. 05-1426, 463 F.3d 1299 (Fed. Cir. Aug. 30, 2006), reh'g denied Oct. 26, 2006.

Two things follow that bear directly on your §102 question:

• The CAFC invalidated under §103(a), not §102. So strictly speaking, nothing on the face of '611 anticipated claim 1 — the kit claim fell to obviousness.
• The decisive art was prior public use / printed instructions, not a cited patent. This is consistent with the §102(a)/(b)/public-use exposure created by the Essix/Tru-Tain commercial-retainer and Warunek/Kesling printed-publication citations in Table A.
• Claims 4, 5, 6 (≥2, ≥10, ≥25 intermediate appliances) and claims 8, 9, 10 (marking by sequential numbering / tags / pouch) were not reached by that ruling — i.e., the "how many stages" and "how marked/packaged" limitations are the ones the cited art did not reach.

§102 bucketing by claim (your specific ask)

• Claim 1 (independent) — no true §102 anticipation found. Requires ≥3 staged polymeric shell aligners + ordering instructions + single package to the patient + pre-planned at outset. The nearest references (Warunek 1989; Essix/Tru-Tain; Truax) each supply only portions. Exposure is §102(b) printed publication / §102(a)–(b) public use in character, but the full combination was defeated only under §103.
• Claim 2 (polymeric shell, cavity, resilient repositioning) — highest §102(b) exposure. Kesling (1945/46), Warunek (1989), and the positioner-manufacture cluster (US 4,755,139 / 4,798,534 / 4,856,991 / 5,035,613 / 5,055,039 / 5,059,118 / 5,186,623) all squarely teach molded polymer shells with tooth-receiving cavities. This is the claim most exposed to outright §102(b) anticipation.
• Claim 3 (successive geometries differ ≤2 mm) — no cited reference quantifies per-stage movement to ≤2 mm, so no true §102 anticipation; the CAFC nonetheless reached it under §103 in combination. ± Claim 3 is a numerical-range limitation no cited patent supplies.
• Claims 4, 5, 6 (≥2 / ≥10 / ≥25 intermediate appliances) — no cited reference discloses these counts. Lowest risk.
• Claims 7, 8, 9, 10 (order marking; direct numbering; tags; pouches) — claim 7 fell under §103 via the Truax instruction sheet/instruction-labeling theory; claims 8–10 (specific marking modalities) were not reached. Note the packaging element is the crux of claim 1, and the closest art is the FDA-labeling theory — i.e., §102(b) public use of a labeled, packaged set.

Procedural caveat on the §102(b) critical date: Because '611 is a continuation of 09/466,353 → PCT/US98/12861 → CIP of 08/947,080 → provisional 60/050,342, the §102(b) critical date is either 1996-06-20 (if entitled to the provisional) or 1996-10-08 (if the kit subject matter first appeared in the Oct. 8, 1997 application). Google Patents lists the priority date as 1997-06-20. Which date governs materially changes which of the above references qualify — and I did not verify entitlement in this session.

What I could not verify — stated explicitly

• The USPTO PatentCenter / PTO-1449 "References Cited" table for 10/159,242 is not in the material I could retrieve. I hit the tool-call ceiling. So I cannot confirm that the examiner-cited list matches Table A, nor rule out additional examiner citations. Verify at USPTO PatentCenter / Global Dossier for application 10/159,242.
• Titles and dates in Table A marked ⚠ are from training data; I did not confirm them against USPTO bibliographic records in this session. Do not treat them as authoritative without verification.
• I could not re-verify the "Truax prior practice/instruction sheet" attribution or the "6,544,611" typo question in this session; I am relying on the previously generated section for those.
• The "no 2026 CAFC docket activity" statement from the prior section remains bounded by the sources searched and should not be treated as an exhaustive docket clearance.

Recommended next step: pull the face-of-patent citation list (form PTO-1449 / "References Cited") and the applicant's IDS for application 10/159,242 from USPTO PatentCenter, then reconcile it row-by-row against Table A — and confirm whether the "other patents of interest" list (US 3,660,900; 3,860,803; 4,936,862; 5,273,429; 5,382,164; 5,549,476; 5,645,421) was actually cited by the examiner or merely attorney-noted in the specification.

I'll ground this analysis in the actual prior-art record from the litigation, then map it claim-by-claim.

Obviousness Analysis — U.S. Patent No. 6,554,611 under 35 U.S.C. § 103

Scope note: This builds on the summaries already generated. The bibliographic, claim, and litigation sections above are treated as authoritative; I add only what is needed for the §103 analysis. The prior sections flagged a 6,544,611 vs. 6,554,611 rendering discrepancy — note that the Align press release reproduced in my searches again uses "6,544,611," while the Federal Circuit opinion, Casetext, CourtListener, and Google Patents all use 6,554,611. I analyze 6,554,611. No contradiction with the prior sections; the discrepancy simply recurs across sources.

Governing law. Priority is 1997‑06‑20, so pre‑AIA 35 U.S.C. § 103(a) governs, as the Federal Circuit in fact applied (Ormco Corp. v. Align Tech., Inc., 463 F.3d 1299 (Fed. Cir. 2006), applying § 102(a)/§ 103(a) (2000)). The Graham v. John Deere factors frame the inquiry; the Federal Circuit's actual holding — claims 1, 2, 3, and 7 invalid as obvious — is the single most probative datum and is treated below as the anchor.

1. Level of ordinary skill in the art

The Federal Circuit did not formally state a level of skill. My reasoned construct (flag: this is my inference, not a holding): a person with an orthodontic or dental-laboratory background — e.g., a practicing orthodontist or a certified dental technician with several years of experience fabricating Kesling-type positioners — or alternatively a mechanical/computer‑graphics engineer working with such a clinician. The "problem" was not a computational one; it was how to move a patient's teeth with a sequence of removable appliances.

2. Prior art inventory (drawn from this patent's own background-art list plus the litigation record)

Flag: Nahoum appears in this family's background-art discussion (I retrieved it from the sibling/descendant applications' specification text, e.g., US 7,074,038), not in the background section quoted on the Google Patents page for the '611 patent itself. Treat it as family-level rather than patent-page-level art.

Flag: US 5,975,893 (the '611's own parent) and WO 98/58596 disclose "sequential numbering" marking and the single-package concept, but they are members of the same priority chain and are therefore not available as prior art against the '611 patent. I do not rely on them.

3. Claim 1 — the primary rejection

Combination A: Truax practice/instruction sheet + FDA device-labeling regulations.

This is precisely the combination the Federal Circuit adopted, and it renders claim 1 obvious. Element-by-element:

• "first appliance … one or more intermediate appliances … a final appliance having geometries selected to reposition/progressively reposition the teeth" — Truax made three appliances at one time from a single repositioned mold, each with a different thickness, applied thinner-first. The district court read "geometry" to require changed cavity positions; the Federal Circuit rejected that construction, held the specification described only preferred embodiments and did not define the term, resorted to dictionaries ("geometry" = "configuration" or "shape"), and concluded that "objects of different thicknesses plainly have different 'configurations' or 'shapes.'" The specification's own concession that the methods "can employ any of the known positioners, retainers, or other removable appliances" reinforced that result.
• "instructions which set forth that the patient is to wear the individual appliances in a predetermined order" — Truax's instruction sheet directed the order (thinner before thicker) and the replacement interval (14–21 days).
• "provided in a single package to the patient" — the court rejected Align's "capable of" construction and held the claim requires actual single-package provision; but it held this adds nothing patentable: "[p]roviding the devices to the patient in one package, as opposed to two packages or three packages is not a novel or patentable feature in the light of the well-known practice of packaging items in the manner most convenient to the purchaser" (slip op. at 16).

Motivation to combine (why a PHOSITA would have made the modification):

1. Routine labeling / known clinical practice. FDA statutes and regulations require instructions with medical devices; the court noted Align conceded at oral argument that providing instructions on how to use a medical device was obvious. This supplies an express KSR-style "design incentive" rooted in a regulatory obligation.
2. Packaging convenience. Consolidating items for the purchaser's convenience is a long-standing, non-technical practice — the court's "manner most convenient to the purchaser" rationale.
3. No teaching away. Align argued Truax taught away from one-time provision (Dr. Truax: "No, because we want to manage it … [i]t would be ridiculous"; the orthodontist must judge tooth movement). The court rejected this because the claims contain no requirement that the appliances be substitutable by the patient and the specification itself contemplates periodic dentist visits in the claimed treatment. A reference only teaches away when it "would be discouraged from following the path set out in the reference" (In re Kahn); Truax's preference for clinician-managed substitution is a preference for a practice, not a disparagement of a single package.
4. Same field, same problem, same solution mechanism. Truax and the '611 patent address the identical problem (avoiding archwire readjustment visits by using multiple removable plastic appliances); combination requires no change in principle of operation — the "art recognized the problem" rationale (Brown & Williamson).
5. Motivation need not be explicit. The court relied on In re Kahn/In re Kotzab: "the teaching, motivation, or suggestion may be implicit from the prior art as a whole."

Alternative primary combination if Truax were held non-analogous or non-enabling: Kesling (1946) + Rains + one of the positioner-manufacture patents (e.g., US 4,798,534 or US 5,186,623). Kesling expressly proposed a series of positioners for graduated movement; Rains built a three-retainer series; Abbatte/Breads teach molding a resilient polymeric shell with a tooth-receiving cavity. In fact, Rains anticipated claims 1–3 and 11–13 of companion patent 6,398,548 (a method claim), which renders the apparatus counterpart in '611 claim 1 obvious a fortiori — the same disclosure applied to the product that performs it.

4. Claims 2 and 3

Claim 2 (polymeric shells with cavities shaped to receive and resiliently reposition teeth): obvious over Truax + any of US 4,755,139 / 4,798,534 / 4,856,991 / 5,035,613 / 5,055,039 / 5,059,118 / 5,186,623, or over Kesling. Truax's appliances were clear plastic dental appliances fitting over the teeth; the "molded shell with a tooth-receiving cavity" is the definitional structure of a Kesling positioner and of the very patents the '611 specification cites for "the manufacture of orthodontic positioners." Motivation: one of ordinary skill seeking Truax's multi-appliance regimen in a removable, bracket-free form would use the standard positioner architecture; no new principle of operation.

Claim 3 (cavity-defined tooth positions differing by ≤2 mm between successive appliances): obvious over Truax alone. Under the Federal Circuit's construction, Truax's appliances are made from the same repositioned mold and differ only in thickness, so the cavity positions of successive appliances differ by 0 mm — comfortably within the "no more than 2 mm" recitation. In the alternative, over Kesling 1946/Rains: expressing the per-stage increment as a numerical upper bound is a result-effective-variable/range limitation, and ranges that overlap or touch a prior-art range are prima facie obvious (In re Geisler; In re Malagari, both cited in the opinion's range discussion).

5. Claims 4, 5, and 6 — the "number of intermediate appliances" ladder

These were not at issue in Ormco and were not adjudicated (Align's statement confirms only four of ten claims were invalidated). But because each depends from claim 1, and claim 1 is invalid, the dependent claims cannot stand on the limitations they add unless those limitations independently confer patentability. Analysis:

• Claim 4 (≥2 intermediate appliances): Truax's three-appliance set maps directly onto first/intermediate/final. Obvious.
• Claim 5 (≥10) and Claim 6 (≥25): These are where the obviousness case is strongest on law but thinnest on record. The combination would be **Kesling (1946, series for graduated movement) or Warunek (series of 2–3 positioners) or Rains + a digital treatment-planning reference (US 5,607,305 / 5,587,912 Andreiko et al.; US 5,011,405 Lemchen; US 5,605,459; Kuroda 1996)**. Motivation: (i) once the number of stages is a free design parameter, decreasing per-stage movement and increasing stage count is the predictable way to reduce force, discomfort, and iatrogenic root/periodontal insult — precisely the trade-off the '611 specification itself recites; (ii) digital manipulation of tooth contours was routine by 1997, making generation of 10–25 intermediate geometries a matter of computational degree, not invention; (iii) Nahoum's "two or more vacuum-formed appliances" shows the count was treated as arbitrary. Under In re Aller / In re Geisler, a change in a numerical range that produces no unexpected result is obvious.

Residual risk (stated honestly): a patentee could argue these are "results-effective" ranges producing unexpected clinical benefit, and I found no record evidence that any prior art expressly disclosed 10 or 25 discrete aligner stages. The obviousness conclusion for claims 5–6 therefore rests on optimization-of-a-recognized-parameter reasoning (fully consistent with KSR's "design incentives and other market forces" and "obvious to try" rationales, though KSR post-dates the 2006 decision), not on anticipation.

6. Claims 7, 8, 9, and 10 — the marking/packaging ladder

• Claim 7 (appliances "marked to indicate their order of use"): expressly held obvious. The Federal Circuit found that "the thicknesses of Truax's devices served as markings to indicate their order of use." Truax's thinner-before-thicker convention is a perceptible, order-conveying physical indicium. Obvious over Truax alone.
• Claims 8, 9, 10 (sequential numbering on the appliances; on tags affixed to them; by placement in a pouch): not adjudicated, but they are pure labeling/packaging conventions. The CAFC's own packaging rationale ("the well-known practice of packaging items in the manner most convenient to the purchaser") disposes of claim 10 almost verbatim — an aligner individually pouched and numbered by stage is the standard way one would package a numbered series of anything. Claims 8–9 add no structural difference from claim 7 other than the medium of the marking (surface, tag, pouch), a choice among known alternatives with predictable results (In re O'Farrell-type reasoning). Weakest link: I found no single pre-1997 reference expressly showing sequential numbers printed on a dental positioner; the case for 8–9 is a common-sense/known-workmanship case with a Truax base, stronger under KSR than under 2006-era Federal Circuit doctrine.

7. Secondary considerations

The court addressed and rejected Align's objective indicia:

• Commercial success (Invisalign): no nexus. The court found the success attributable to unclaimed features — transparency without brackets/wires, comfort, removability for hygiene, and "the computerized design and manufacture of the aligners." J.T. Eaton / Brown & Williamson: success from unclaimed features is irrelevant; so too if the feature was already known in the prior art. Notably, the time savings from multiple appliances was "not new; Truax had already accomplished this."
• Long-felt need / failure of others: likewise rejected for lack of nexus.
• Teaching away: rejected as to single-package provision, per §3 above.

This matters analytically: for the unadjudicated dependent claims, a nexus argument would likewise have to run through the added limitations (e.g., ≥25 stages, numbering), because the base claim's commercial-success argument already failed.

8. Bottom line

Because claim 1 is invalid, every dependent claim (4–6, 8–10) incorporates an invalid limitation and is at minimum prima facie invalid; only a showing that the added limitation independently confers nonobviousness could save them — and the record evidence I found does not support such a showing. The patent's anticipated expiration was 2017‑10‑08, so this analysis is retrospective.

9. Explicit uncertainty / coverage gaps

• Level of ordinary skill is my construct; the Federal Circuit opinion does not state one.
• Claims 4–6 and 8–10 were never adjudicated; my treatment of them is reasoned analysis, not precedent. I state no higher confidence than "moderate" for 5–6 and 8–10.
• FDA citations (21 U.S.C. § 352(f); 21 C.F.R. § 801.5 et seq.): the court referred generally to "regulations of the Food and Drug Administration … that generally require the provision of instructions with medical devices." I have not independently verified the precise statutory/CFR sections and flag them as my characterization.
• Nahoum (1964) is family-level, not patent-page-level, art (flag repeated).
• I did not locate a single pre-1997 reference expressly showing sequential numbering printed on an aligner (claims 8–9), or any reference expressly disclosing ≥10 or ≥25 discrete aligner stages (claims 5–6).
• The "geometry = thickness" construction is essential to Combination A. If a later tribunal departed from Ormco's dictionary-based construction and imported the specification's different-cavity-position embodiment (contrary to Phillips), Combination A weakens for claim 1 — but Combination B (Kesling 1946 + Rains + Abbatte/Breads) would then carry the analysis, since Rains' retainers were made from successive molds with genuinely different cavity positions.

Primary sources for this section: Federal Circuit opinion, 463 F.3d 1299 — https://cases.justia.com/federal/appellate-courts/cafc/05-1426/05-1426-2011-03-27.pdf, https://www.courtlistener.com/opinion/211087/ormco-corporation-v-align-technology/, http://g.casetext.com/case/ormco-corp-v-align-technology-inc-2; Finnegan, "Last Month at the Federal Circuit," Sept. 2006 — http://www.finnegan.com/files/Publication/cd345b72-13ad-465a-8c80-7f6c828c7032/.../Last%20Month%20at%20the%20Federal%20Circuit%20September%202006.pdf; Align press release, Aug. 31, 2006 — https://aligntech.gcs-web.com/news-releases/news-release-details/federal-circuit-court-appeals-reverses-district-court-and-finds; patent page — https://patents.google.com/patent/US6554611/en.